Skip to content

Beta Blocker De-prescription Following Coronary Artery Bypass Graft Surgery (BEEFBURGER Trial).

Coronary Artery Disease | ST Elevation Myocardial Infarction | Coronary Artery Stenosis | Acute Myocardial...

Beta-blockers have the greatest cardiovascular impact in patients with reduced heart function/heart failure and in reducing the peri-operative risk of atrial fibrillation. In patients without these high-risk features treated with coronary artery bypass graft (CABG) surgery, their continued long-term role is unclear.

null

Participation Requirements

  • Sex:

    ALL

  • Eligible Ages:

    18 and up

Participation Criteria

Inclusion Criteria:

* Age ≥ 18 years treated with index isolated CABG
* Able to consent to study
* On beta blocker therapy at the 6-8week visit
* LV systolic function (≥45% assessed within 6months of CABG date)

Exclusion Criteria:

* Prior heart failure with reduced ejection fraction (LVEF \<45%)
* Pre- or peri-operative atrial fibrillation or flutter
* Peri-CABG stroke
* Unable to follow-up

Study Location

Royal University Hospital
Royal University Hospital
Saskatoon, Saskatchewan
Canada

Contact Study Team

Primary Contact

Jay Shavadia, MD

[email protected]
3069862260
Study Sponsored By
University of Saskatchewan
Participants Required
More Information
Study ID: NCT04788186